[Form 4] Senti Biosciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

UWM Holdings (UWMC) Form 4: CEO, President and 10 % owner Mat Ishbia, acting through affiliate SFS Corp, disclosed two open-market sales of Class A common shares executed under a Rule 10b5-1 plan adopted 17 Mar 2025.

• 18 Jul 2025: 400,036 shares sold at a weighted-average $4.20 (range $4.15–$4.24).
• 21 Jul 2025: 400,036 shares sold at a weighted-average $4.40 (range $4.25–$4.48).

Total disposition: 800,072 shares, ≈17.8 % of the 4.50 million shares SFS held before the first sale. Post-sale indirect ownership stands at 3,699,172 shares; Ishbia also directly owns 279,989 shares.

The filing lists 180,737 unvested RSUs, convertible 1-for-1, that vest 1 Mar 2026. No derivative exercises were reported.

The transactions reduce but do not eliminate Ishbia’s exposure, yet sizable insider selling by the top executive may weigh on investor sentiment.

Insights

Equity Analyst

TL;DR: CEO sold 800k shares (~18 %), still holds 3.7 m; sale under 10b5-1, sentiment mildly negative.

Mat Ishbia’s divestiture is material given his position and the absolute size of the trades. Although executed under a pre-arranged plan, disposing nearly one-fifth of his indirect holdings in two sessions is likely to be interpreted as reduced near-term confidence. Post-sale ownership remains significant, preserving alignment, and RSUs add a future stake, partially mitigating concerns. Nonetheless, the quick succession of sales at only ~4 $ per share, well below the de-SPAC price, creates an overhang and could pressure the stock.

Corporate Governance Expert

TL;DR: Pre-planned sales comply with Rule 10b5-1; governance clean, market perception still cautious.

The use of a 10b5-1 plan limits allegations of opportunistic trading and reflects sound governance practice. Disclosure includes weighted-average pricing and confirms Ishbia’s ongoing >10 % ownership, satisfying transparency standards. However, investors often view concentrated executive selling as a negative signal regardless of compliance. Overall impact: modestly adverse to sentiment but not indicative of operational issues.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Baum Bryan Daniel

(Last) (First) (Middle)

C/O SENTI BIOSCIENCES, INC.

2 CORPORATE DR, FIRST FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Senti Biosciences, Inc. [ SNTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.95	07/18/2025		A		43,900		(1)	07/18/2035	Common Stock	43,900	$0	43,900	D

Explanation of Responses:

1. The shares underlying this option vest in 36 substantially equal monthly installments over three years from July 18, 2025, subject to the reporting person's continued service through the applicable vesting date.

Remarks:

	/s/ Robert Cutler, attorney-in-fact	07/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.